ERG Components in Schizophrenia and Bipolar Disorder Type I (NCT03788811)
Assessment of ERG Components to Discriminate Between Schizophrenia and Bipolar Disorder Type I
🩺 Plain-English Summary (8th-Grade Level)
This study will further assess ERG components obtained with different ERG devices, to be considered in a prediction model for each diagnosis. The prediction models are diaMentis proprietary software used as an ERG-based diagnostic test (classified as a Software as Medical Device, SaMD) to support the diagnosis of schizophrenia and bipolar disorder type I. They involve the processing and analysis of specific retinal biosignatures (RSPA) with the support of statistical and mathematical modelling processes e.g. machine learning and statistical learning.
Who can join: Review the eligibility criteria below.
Location: Collaborative Neuroscience Research LLC — Garden Grove, California
Age range: 18 Years to 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Collaborative Neuroscience Research LLC — Garden Grove, California
- Synergy San Diego — Lemon Grove, California
- Collaborative Neuroscience Research LLC — Torrance, California
- Segal trials West Broward Outpatient Site — Lauderhill, Florida
- Segal Trials Miami Lakes Medical Research — Miami Lakes, Florida
- McLean Hospital — Belmont, Massachusetts
- Rutgers University Behavioral HealthCare — Piscataway, New Jersey
- The Zucker Hillside Hospital — Glen Oaks, New York
- University of Rochester Medical Center — Rochester, New York
- Richmond Behavioral Associates — Staten Island, New York
- University Hills Clinical Research — Irving, Texas
- Monash Medical Centre — Clayton, Victoria
- Barwon Health University Hospital — Geelong, Victoria
- Albert Road Clinic — Melbourne, Victoria
- Queen's University — Kingston, Ontario
- Centre for Addiction and Mental Health (CAMH) — Toronto, Ontario
- Institut Universitaire en Santé Mentale de Montréal — Montreal, Quebec
- Douglas Mental Health University Institute — Montreal, Quebec
- CISSS-CA Hôpital de Saint-Georges — Saint-Georges, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Schizophrenia
- Young Adults With Violent Behavior During Early Psychosis (Aim 2) — New York, New York
- Does tDCS Change Synaptic Density in the Brains of Patients With Schizophrenia — Toronto, Ontario
- Ketogenic Diet in People With Schizophrenia — Catonsville, Maryland
- Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia — Toronto, Ontario
- Investigating the Muscarinic System in Schizophrenia Using Positron Emission Tomography — Toronto, Ontario
- Long-Term Real-World Safety of Cobenfy in Adults With Schizophrenia — Suwanee, Georgia
Explore by condition: All Schizophrenia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.